⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GPCR News
Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
globenewswire.com
GPCR
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
globenewswire.com
MDBH
LLY
NVO
PFE
AZN
GILD
GPCR
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
globenewswire.com
GPCR
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
globenewswire.com
GPCR
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
globenewswire.com
GPCR
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
globenewswire.com
GPCR
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
globenewswire.com
GPCR
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
globenewswire.com
GPCR
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
globenewswire.com
GPCR